About Native Antigen
Native Antigen is a Healthcare company based in Upper Heyford (United Kingdom) founded in 2010, and was acquired by LGC in July 2020. Development and manufacture of native and recombinant viral and bacterial antigens. Native Antigen has raised $1.1 million across 5 funding rounds from investors including Mercia and LGC. The company has 28 employees. Its website thenativeantigencompany.com draws about 19 thousand monthly visits. Native Antigen offers products and services including Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is THE NATIVE ANTIGEN COMPANY LIMITED.
Company details
Founded in 2010, Native Antigen is based in Upper Heyford, United Kingdom, and operates in the biotechnology sector. Native and recombinant viral and bacterial antigens are developed and manufactured for use by pharmaceutical and in vitro diagnostic manufacturers in vaccine research and serology applications, where proper folding and glycosylation are required. Bespoke product development and custom manufacturing are also undertaken using a proprietary mammalian cell protein expression system.
- Headquarters Upper Heyford, United Kingdom
- Employees 28
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website thenativeantigencompany.com
- Social LinkedIn X
- Acquired by LGC (Jul 2020)
- Legal Name The Native Antigen Company Limited
- Date of Incorporation 23 Sep, 2010
- Jurisdiction TEDDINGTON, ENGLAND
Products & Services of Native Antigen
Native Antigen offers a comprehensive portfolio of products and services, including Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits.
Products for detecting viral and bacterial pathogens in research.
Simulated particles for vaccine and diagnostic development.
Kits for antibody detection in disease testing.
Substances for studying bacterial infections.
Kits for labeling proteins in assays.
Funding Insights of Native Antigen
Native Antigen has successfully raised a total of $1.1M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $179.72 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.1M
- Total Rounds 5
- Last Round Series A — $179,723
- First Round $449,648
(Dec 2010)
- Investors Count 1
All 5 funding rounds of Native Antigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $179,723 | Series A | – | – | – |
| Nov 2014 | $298,181 | Series A | – | – | – |
| Apr 2013 | Series A | – | Mercia | – | |
| Oct 2011 | $171,087 | Seed | – | – | – |
| Dec 2010 | $449,648 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Native Antigen
Native Antigen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Mercia and LGC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | ||
Molecular biology reagents and services are supplied to biotech industries. | 1842 | lgcgroup.com | Teddington, United Kingdom |
Investor details for Native Antigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Native Antigen
4 dated milestones of Native Antigen across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Native Antigen is founded.
- Funding First funding round of $450K.
- Funding Latest funding round, Series A, of $180K.
- Exit Acquired by LGC.
Web traffic of Native Antigen
The website of Native Antigen (thenativeantigencompany.com) receives about 18.8K visits a month.
- Monthly visits18.8K
▲ 11.5% vs previous month
Websites whose visitors overlap most with Native Antigen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genetex.com | 100% | 48.7K | #686,186 | View details | |
smcmvcd.org | smcmvcd.org | 98% | #1,930,916 | – | |
| icllab.com | 94% | 8.7K | #2,336,373 | View details | |
affbiotech.com | affbiotech.com | 94% | #1,549,129 | – | |
| sinobiological.com | 91% | 188.9K | #224,370 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Native Antigen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Native Antigen (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Native Antigen
Complete news archive for Native Antigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Native Antigen
Native Antigen was founded in 2010.
Native Antigen is headquartered in Upper Heyford, United Kingdom. It is registered at Upper Heyford, England, United Kingdom.
Native Antigen is a funded company, having raised a total of $1.1M across 5 funding rounds to date. The company's 1st funding round was a Seed of $449.65K, raised on Dec 2010.
Native Antigen has 28 employees.
Founded in 2010, Native Antigen is based in Upper Heyford, United Kingdom, and operates in the biotechnology sector. Native and recombinant viral and bacterial antigens are developed and manufactured for use by pharmaceutical and in vitro diagnostic manufacturers in vaccine research and serology applications, where proper folding and glycosylation are required. Bespoke product development and custom manufacturing are also undertaken using a proprietary mammalian cell protein expression system.
Native Antigen offers Antigens and Antibodies, Virus-Like Particles, Immunoassays, Toxins, and Protein Conjugation Kits.
Native Antigen operates through The Native Antigen Company Limited.
Yes. Native Antigen was acquired by LGC in July 2020.